Evidence map›Paper›PMID 39205642›Full record

ArticleActa biochimica et biophysica Sinica2024

TCF3 as a multidimensional biomarker: oncogenicity, genomic alterations, and immune landscape in pan-cancer analysis.

Huiling Nie, Yang Yu, Siqi Zhou, Yue Xu, Xi Chen, Xun Qin, Zhangyu Liu, Jiayu Huang, Hailiang Zhang, Jin Yao and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Acta biochimica et biophysica Sinica, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Huiling NieThe Affiliated Eye Hospital and the Fourth School of Clinical Medicine, Nanjing Medical University, Nanjing 210004, China.
Yang YuThe Affiliated Eye Hospital and the Fourth School of Clinical Medicine, Nanjing Medical University, Nanjing 210004, China.
Siqi ZhouDepartment of Urology, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China.
Yue XuDepartment of Ophthalmology, the Fourth Affiliated Hospital of Soochow University, Suzhou 215002, China.
Xi ChenThe Affiliated Eye Hospital and the Fourth School of Clinical Medicine, Nanjing Medical University, Nanjing 210004, China.
Xun QinThe Affiliated Eye Hospital and the Fourth School of Clinical Medicine, Nanjing Medical University, Nanjing 210004, China.
Zhangyu LiuThe Affiliated Eye Hospital and the Fourth School of Clinical Medicine, Nanjing Medical University, Nanjing 210004, China.
Jiayu HuangThe Affiliated Eye Hospital and the Fourth School of Clinical Medicine, Nanjing Medical University, Nanjing 210004, China.
Hailiang ZhangDepartment of Urology, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China.
Jin YaoThe Affiliated Eye Hospital and the Fourth School of Clinical Medicine, Nanjing Medical University, Nanjing 210004, China.
Qin JiangThe Affiliated Eye Hospital and the Fourth School of Clinical Medicine, Nanjing Medical University, Nanjing 210004, China.
Bingbing WeiDepartment of Urology, the Affiliated Wuxi People's Hospital of Nanjing Medical University, Wuxi 214023, China.
Xiaojian QinDepartment of Urology, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Transcription factor 3 (TCF3), a pivotal member of the TCF/LEF family, plays a critical role in tumorigenesis. Nonetheless, its impact on the tumor microenvironment (TME) and cancer phenotypes remains elusive. We perform an exhaustive analysis of TCF3 expression, DNA variation profiles, prognostic implications, and associations with the TME and immunological aspects. This study is based on a large-scale pan-cancer cohort, encompassing over 17,000 cancer patients from multiple independent datasets, validated by

Indexed as

Basic Helix-Loop-Helix ProteinsBiomarkers, TumorNeoplasmsCarcinogenesisCell Line, TumorEpithelial-Mesenchymal TransitionGene Expression Regulation, NeoplasticHumansMutationPrognosisTumor MicroenvironmentBasic Helix-Loop-Helix ProteinsBiomarkers, TumorTCF3 protein, humanepithelial-mesenchymal transition (EMT)pan-cancer analysisprognosisTCF3TCF/LEF familytumor microenvironment (TME)

Identifiers

PMID39205642
PMCPMC11868920

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.